Patient views on long-acting injection treatment for HIV in Belgium
Studies how people with HIV feel about cabotegravir and rilpivirine injections.
Plain-language title generated from the registry record
Registry title: Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
Key facts
- Where
- Brussels, BelgiumSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06424964, who can take part
Where in Belgium
- Saint-Pierre University HospitalBrussels, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Belgian Research on AIDS and HIV Consortium
- Trial code
- NCT06424964
- Record updated
- 5 February 2025
- Original description
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.Read full original descriptionShow less
Use of Long-Acting Injectable Cabotegravir/Rilpivirine for the Treatment of HIV in Belgium
This will be a multi-center, single arm observational cohort study with an assessment of patient-reported outcomes (PROs) and of clinical and virologic outcomes.
Primary outcome • Evaluate patient perception of, and satisfaction with, long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) for the treatment of HIV
Secondary outcomes
• Description of the demographic, HIV-, and non-HIV-related characteristics of participants included in this analysis
Inclusion: HIV-1 patients, aged 18 years and above, having received at least 1 dose of LAI CAB/RPV between September 1, 2021, and March 31, 2024.